Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba6d83d18577ee5f8be9bbfc4f0d17a97> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba6d83d18577ee5f8be9bbfc4f0d17a97 NCIT_P378 "NCI" @default.
- Ba6d83d18577ee5f8be9bbfc4f0d17a97 type Axiom @default.
- Ba6d83d18577ee5f8be9bbfc4f0d17a97 annotatedProperty IAO_0000115 @default.
- Ba6d83d18577ee5f8be9bbfc4f0d17a97 annotatedSource NCIT_C103860 @default.
- Ba6d83d18577ee5f8be9bbfc4f0d17a97 annotatedTarget "A humanized IgG4 monoclonal antibody that targets the human leukocyte antigen HLA-DR, with potential antineoplastic activity. Upon administration, anti-HLA-DR monoclonal antibody IMMU-114 binds to HLA-DR on HLA-DR-expressing tumor cells and, although the exact mechanism has yet to be fully elucidated, appears to induce hyperactivation of ERK- and JNK-dependent mitogen activated protein kinase signaling pathways. This may lead to mitochondrial membrane depolarization and reactive oxygen species (ROS) generation. This eventually leads to an induction of tumor cell apoptosis and a reduction in tumor cell proliferation. IMMU-14 may be beneficial in the treatment of graft versus host disease (GVHD) as it appears to suppress T-lymphocyte proliferation and natural killer (NK) cell activation. As the Fc region of the orgnial IgG1 MoAb was replaced with the IgG4 isotype, IMMU-114 does not induce a complement cytotoxicity (CDC) or an antibody-dependent cell-mediated cytotoxicity (ADCC). HLA-DR, a MHC class II molecule, is found on various b-cell hematologic malignancies and in autoimmune diseases as well as on normal cells." @default.